Table 1 Characteristics of T-ALL patients according to WT1 mutational status

From: Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies

 

Total

WT1 wild-type

WT1 mutant

P-value

 

No. (%)

No. (%)

No. (%)

 

Patients

143 (100%)

128 (90%)

15 (10%)

 

Age (years)

 Median

8.9

9.0

7.7

0.678

 Range

1.2–17.3

1.2–17.3

4.8–16.5

 

Sex

 Male

107 (75%)

96 (75%)

11 (73%)

1.0

 Female

36 (25%)

32 (25%)

4 (27%)

 

WBC count (10 9 /l)

 Median

54.6

54.6

45.5

0.886

 Range

0.2–872.0

0.2–872.0

1.0–415.0

 

Mediastinal involvement

 No

79 (58%)

71 (58%)

8 (53%)

0.785

 Yes

58 (42%)

51 (42%)

7 (47%)

 

 Missing

6

6

0

 

Response to prephase

 <1000 blasts per μl

91 (64%)

83 (65%)

8 (53%)

0.400

1000 blasts per μl

51 (36%)

44 (35%)

7 (47%)

 

 Missing

1 (1%)

1 (1%)

0 (0%)

 

Minimal residual disease (MRD)

 <10−2

80 (83%)

75 (84%)

5 (71%)

0.330

10−2

16 (17%)

14 (16%)

2 (29%)

 

 Absence of markers

4 (3%)

4 (3%)

0 (0%)

 

 Missing or ND

43 (30%)

35 (27%)

8 (53%)

 

Very high risk (VHR)

 No

84 (61%)

77 (63%)

7 (47%)

0.269

 Yes

54 (39%)

46 (37%)

8 (53%)

 

 Missing

5 (3%)

5 (4%)

0 (0%)

 

Immunophenotype (EGIL)

 Early (TI/TII)

37 (33%)

31 (31%)

6 (46%)

0.353*

 Cortical (TIII)

49 (44%)

45 (46%)

4 (31%)

 

 Mature (TIV)

26 (23%)

23 (23%)

3 (23%)

 

 T-lineage (no further specified)

31 (22%)

29 (23%)

2 (13%)

 

Oncogenic classifying alterations

SIL-TAL (+)

20 (14%)

20 (16%)

0 (0%)

0.130

HOX11/TLX1 (+)

9 (6%)

7 (5%)

2 (13%)

0.240

HOX11L2/TLX3 (+)

31 (22%)

23 (18%)

8 (53%)

0.004

CALM-AF10 (+)

6/110 (5%)

6/98 (6%)

0/12 (0%)

1.0

MLL rearrangement

5 (3%)

4 (3%)

1 (7%)

0.430

 Other HOXA10 (+)

3/70 (4%)

2/64 (3%)

1/6 (17%)

0.492

Other genetic alterations

NUP214-ABL (+)

9/129 (7%)

7/115 (6%)

2/14 (14%)

0.253

MYB duplication (+)

7/70 (10%)

6/62 (10%)

1/8 (12%)

1.0

NOTCH1 mut and/or FBXW7 mut

78/131 (60%)

70/118 (59%)

8/13 (62%)

1.0

  1. Abbreviations: EGIL, European group for the immunological characterization of leukemias; mut, mutated; ND, not done; T-ALL, T-lineage acute lymphoblastic leukemia; WBC, white blood cell; WT1, Wilms tumor 1.
  2. Percentages between ( ) were calculated taking into account only documented cases.
  3. *P-value calculated for comparison of early-T versus cortical-T and mature-T.